CLINICAL UPDATES
 
FDA approves new drug for UTI, two devices for OAB/incontinence
The FDA recently gave the green light to a new drug for complicated urinary tract infection, an implantable device for the treatment of overactive bladder/retention, and a digital product for strengthening of pelvic floor muscles and treatment of urinary incontinence in women.
Learn more
 
OnabotA safe in patients taking anticoagulants
As the number of patients who receive onabotulinumtoxinA (onabotA [Botox]) injections for overactive bladder increases, so does the age of this population and their associated comorbidities. This raises the question: Is the use of onabotA in patients who are taking anticoagulant or antiplatelet medication safe?
Get the data
 
 
ADVERTISEMENT
Achieving a high success rate with large stones
Seth K. Bechis, MD, discusses a percutaneous approach to treating a 52-year-old patient with a large 4cm obstructed proximal ureteral stone. He highlights the steps and tools used in his technique, including effective lithotripter settings.
Watch the video now.
 
SURVEY
 
Is DRE still a relevant tool in the management of prostate cancer?
MORE FROM UROLOGY TIMES
 
Positive dipstick does not preclude BTX injections
New data point to statins’ potential for reducing prostate growth
ADVERTISEMENT
Optimizing treatment decisions in mCRPC
In this Urology Times® supplement, a roundtable of expert urologists and oncologists addresses common questions about patient evaluation and management of castration-resistant prostate cancer (CRPC) and high-risk metastatic hormone-sensitive prostate cancer (mHSPC), including the role and impact of the commercially available androgen receptor splice variant 7 (AR-V7) test to guide treatment decisions for men with metastatic CRPC.
Read it now
 
JOB OPPORTUNITIES
 
NY-WNY Urology Associates
VT-University of Vermont
VT-University of Vermont